Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | DTYMK | P23919 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12410769 | 0.86 | MEN1 (0.43) | MEN1KMT2ADTYMK | |
| SCHEMBL17243361 | 0.81 | HPGD (0.52) | — | |
| SCHEMBL12499920 | 0.81 | DAO (0.41) | DAOMEN1KMT2A | |
| SCHEMBL1557291 | 0.80 | HPGD (0.58) | DAOMEN1KMT2ADTYMK | |
| SCHEMBL12499618 | 0.80 | MEN1 (0.58) | DAOMEN1KMT2ADTYMK | |
| SCHEMBL12410818 | 0.80 | MAPT (0.46) | DAOMEN1KMT2A | |
| SCHEMBL12410770 | 0.80 | MEN1 (0.38) | DAOMEN1KMT2A | |
| SCHEMBL12501020 | 0.79 | MEN1 (0.41) | MEN1KMT2ADTYMK | |
| SCHEMBL12410775 | 0.79 | MEN1 (0.47) | DAOMEN1KMT2A | |
| SCHEMBL5126504 | 0.78 | HPGD (0.62) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181199-B2 | Uracil derivatives and use thereof | RESPROTECT GMBH (DE) | 2015-11-10 | — | — | US | disclosed |
| US-9181199-B2 | Uracil derivatives and use thereof | RESPROTECT GMBH (DE) | 2015-11-10 | — | — | US | disclosed |
| US-9181199-B2 | Uracil derivatives and use thereof | RESPROTECT GMBH (DE) | 2015-11-10 | — | — | US | disclosed |
| US-20110166096-A1 | URACIL DERIVATIVES AND USE THEREOF | RESPROTECT GMBH (DE) | 2011-07-07 | — | — | US | disclosed |
| US-20110166096-A1 | URACIL DERIVATIVES AND USE THEREOF | RESPROTECT GMBH (DE) | 2011-07-07 | — | — | US | disclosed |
| US-20110166096-A1 | URACIL DERIVATIVES AND USE THEREOF | RESPROTECT GMBH (DE) | 2011-07-07 | — | — | US | disclosed |
| WO-2009156182-A2 | URACIL DERIVATIVES AND USE THEREOF | RESPROTECT GMBH (DE) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166096-A1 | URACIL DERIVATIVES AND USE THEREOF | TYMP, UNG, DPYD | DAO 1976/4885MEN1 2207/4885KMT2A 3185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.